Imatinib mesylate (Gleevec) is a clinically available receptor tyrosine kinase inhibitor that is used to treat chronic myeloid leukemia patients long-term with limited side effects. This evidence concerns the gene NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive.